• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    R1 RCM Reports Fourth Quarter and Full Year 2023 Results

    2/27/24 7:00:00 AM ET
    $RCM
    Other Consumer Services
    Consumer Discretionary
    Get the next $RCM alert in real time by email

    MURRAY, Utah, Feb. 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months and year ended December 31, 2023.

    Fourth Quarter 2023 Results:

    • Revenue of $575.1 million, up $41.8 million or 7.8% compared to the same period last year
    • GAAP net income of $1.4 million, compared to a net loss of $36.6 million in the same period last year
    • Adjusted EBITDA of $167.7 million, up $42.1 million or 33.5% compared to the same period last year

    Full Year 2023 Results:

    • Revenue of $2,254.2 million, up $447.8 million or 24.8% compared to 2022
    • GAAP net income of $3.3 million, compared to net loss of $63.3 million in 2022
    • Adjusted EBITDA of $614.3 million, up $190.5 million or 45.0% compared to 2022

    "R1 executed on its key objectives in 2023. We established a stronger foundation for growth, stabilized key metrics for several clients and delivered approximately $30 million in synergies from the Cloudmed integration," stated Lee Rivas, R1's CEO. "In addition, we strengthened our technology platform by driving innovation through generative AI and enhanced our global infrastructure to improve our performance and competitive position in the market."

    Mr. Rivas added, "We enter 2024 with a more diversified business, enhanced technology initiatives and increased global scale. Our strategy is to leverage our best-in-class capabilities to deploy flexible models that meet customers where they are in their revenue cycle journey. We believe R1's breadth of capabilities and data-driven technology platform, combined with our focus on operational excellence, positions us to drive value for our customers while delivering long-term sustainable growth and improved financial performance for our shareholders."

    2024 Outlook

    For 2024, R1 expects to generate:

    • Revenue of between $2,625 million and $2,675 million
    • GAAP operating income of $105 million to $135 million
    • Adjusted EBITDA of $650 million to $670 million

    Jennifer Williams, R1's CFO said, "Our outlook for fiscal 2024 reflects the strength of our platform and our focus on both growth and operating discipline to deliver great value for our customers and shareholders. To further our leadership position in the industry, we will continue improving execution across our business, advancing our new business pipeline and investing in technology, while remaining committed to improving margins and cash flows."

    Supplemental Forward-Looking Information and Assumptions for Fiscal Year 2024

    The Company is providing the following supplemental expectations and related assumptions regarding its fiscal year 2024 results, all of which are subject to change, to further provide transparency to investors:

    • Revenue of $2,625 to $2,675 million assumes the following:
      • Net operating fees and incentive fees remain consistent with the fourth quarter 2023 run rate (excluding Providence and Acclara contributions), with expected low single digit year-over-year cash collection growth offset by customer attrition and facility divestitures.
      • Modular and Other revenue assumes revenue growth in the low teens.
      • We anticipate Acclara and Providence to contribute revenue of approximately $290 to 295 million, and $45 to 50 million, respectively.
    • Capital expenditures of approximately 5% of revenue for the fiscal year.
    • Other expenses for the fiscal year of approximately $105 to $125 million, including integration expenses in connection with the Acclara acquisition.
    • Interest expense in the range of $160 to $165 million for the fiscal year, including the impact of $575 million in additional Term B Loans and the $80 million draw on the Company's senior revolving credit facility related to the Acclara acquisition.
    • Depreciation and amortization expense of $330 to $350 million.

    Conference Call and Webcast Details

    R1's management team will host a conference call today at 8:00 a.m. Eastern Time to discuss its financial results and business outlook. To participate, please dial 888-330-2022 (646-960-0690 outside the U.S. and Canada) using conference code number 5681952. A live webcast and replay of the call will be available at the Investor Relations section of the Company's website at ir.r1rcm.com.

    Non-GAAP Financial Measures

    In order to provide a more comprehensive understanding of the information used by R1's management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP cost of services, non-GAAP selling, general and administrative expenses, and net debt. Adjusted EBITDA is defined as GAAP net income (loss) before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. ("CoyCo 2") share-based compensation expense, and certain other items, including business acquisition costs, integration costs, technology transformation, strategic initiatives, and facility-exit charges. Non-GAAP cost of services is defined as GAAP cost of services less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to cost of services. Non-GAAP selling, general and administrative expenses is defined as GAAP selling, general and administrative expenses less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to selling, general and administrative expenses. Net debt is defined as debt less cash and cash equivalents, inclusive of restricted cash. Adjusted EBITDA guidance is reconciled to operating income guidance, the most closely comparable available GAAP measure.

    The Company's board of directors and management team use adjusted EBITDA as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations and (ii) a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation programs for employees. Non-GAAP cost of services and non-GAAP selling, general and administrative expenses are used to calculate adjusted EBITDA. Net debt is used as a supplemental measure of the Company's liquidity.

    Tables 4 through 9 present a reconciliation of GAAP financial measures to non-GAAP financial measures. Non-GAAP measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release are forward-looking statements. The words "anticipate," "believe," "contemplate," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "outlook," "plan," "predict," "project," "see," "seek," "target," "would" and similar expressions or variations or negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements about the Company's strategy, future operations, future financial position, prospects, plans, objectives of management, ability to successfully deliver on commitments to customers, ability to deploy new business as planned, ability to successfully implement new technologies, and expected market growth. Such forward-looking statements are based on management's current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause the Company's actual results to differ materially from those expressed or implied in its forward-looking statements. Subsequent events and developments, including actual results or changes in the Company's assumptions, may cause the Company's views to change. The Company does not undertake to update its forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. The Company's actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to, economic downturns and market conditions beyond the Company's control, including high inflation; the quality of global financial markets; the Company's ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisitions of Cloudmed and Acclara; the Company's ability to retain existing customers or acquire new customers; the development of markets for the Company's revenue cycle management offering; variability in the lead time of prospective customers; competition within the market; breaches or failures of the Company's information security measures or unauthorized access to a customer's data; delayed or unsuccessful implementation of the Company's technologies or services, or unexpected implementation costs; disruptions in or damages to the Company's global business services centers and third-party operated data centers; the volatility of the Company's stock price; the impact of the recent restatements of the financial statements for the applicable periods on the price of the Company's common stock, reputation and relationships with its investors, suppliers, customers, employees and other parties; the Company's substantial indebtedness; and the factors set forth under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, and any other periodic reports that the Company may file with the U.S. Securities and Exchange Commission.

    About R1 RCM

    R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1's proven and scalable operating models seamlessly complement a healthcare organization's infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

    Contact:

    R1 RCM Inc.

    Investor Relations:

    Evan Smith, CFA

    516-743-5184

    [email protected]

    Media Relations:

    Yancey Casey

    Amendola Communications

    678-895-9401

    [email protected]

     
    Table 1
    R1 RCM Inc.
    Consolidated Balance Sheets
    (In millions)
      (Unaudited)  
      December 31,
       2023   2022 
    Assets    
    Current assets:    
    Cash and cash equivalents $173.6  $110.1 
    Accounts receivable, net of $48.2 million and $15.1 million allowance as of December 31, 2023 and 2022, respectively  243.3   235.2 
    Accounts receivable - related party, net of $0.1 million allowance as of December 31, 2023 and 2022  26.1   25.0 
    Current portion of contract assets, net  94.4   83.9 
    Prepaid expenses and other current assets  95.9   110.3 
    Total current assets  633.3   564.5 
    Property, equipment and software, net  173.7   164.8 
    Operating lease right-of-use assets  62.5   80.5 
    Non-current portion of contract assets, net  37.7   32.0 
    Non-current portion of deferred contract costs  30.4   26.7 
    Intangible assets, net  1,310.7   1,514.5 
    Goodwill  2,629.4   2,640.3 
    Non-current deferred tax assets  10.9   10.4 
    Other assets  71.6   88.1 
    Total assets $4,960.2  $5,121.8 
    Liabilities    
    Current liabilities:    
    Accounts payable $22.7  $33.4 
    Current portion of customer liabilities  39.8   57.5 
    Current portion of customer liabilities - related party  5.2   7.4 
    Accrued compensation and benefits  126.3   109.0 
    Current portion of operating lease liabilities  19.3   18.0 
    Current portion of long-term debt  67.0   53.9 
    Accrued expenses and other current liabilities  65.9   70.5 
    Total current liabilities  346.2   349.7 
    Non-current portion of customer liabilities  2.7   5.0 
    Non-current portion of customer liabilities - related party  11.8   13.7 
    Non-current portion of operating lease liabilities  77.8   94.4 
    Long-term debt  1,570.5   1,732.6 
    Non-current deferred tax liabilities  176.6   200.8 
    Other non-current liabilities  23.2   23.1 
    Total liabilities  2,208.8   2,419.3 
    Stockholders' equity:    
    Common stock  4.5   4.4 
    Additional paid-in capital  3,197.4   3,123.3 
    Accumulated deficit  (136.7)  (140.0)
    Accumulated other comprehensive loss  (5.9)  (3.4)
    Treasury stock  (307.9)  (281.8)
    Total stockholders' equity  2,751.4   2,702.5 
    Total liabilities and stockholders' equity $4,960.2  $5,121.8 



    Table 2
    R1 RCM Inc.
    Consolidated Statements of Operations
    (In millions, except share and per share data)
         
      (Unaudited) (Unaudited) (Unaudited)  
      Three Months Ended December 31, Year Ended December 31,
       2023  2022   2023  2022 
    Net operating fees $369.1 $344.9  $1,455.9 $1,309.7 
    Incentive fees  23.9  25.9   108.4  106.8 
    Modular and other  182.1  162.5   689.9  389.9 
    Net services revenue  575.1  533.3   2,254.2  1,806.4 
    Operating expenses:        
    Cost of services  441.6  435.5   1,769.7  1,446.9 
    Selling, general and administrative  55.7  54.3   220.0  172.5 
    Other expenses  28.7  47.3   116.6  189.8 
    Total operating expenses  526.0  537.1   2,106.3  1,809.2 
    Income (loss) from operations  49.1  (3.8)  147.9  (2.8)
    Net interest expense  31.6  28.7   126.9  64.0 
    Income (loss) before income tax provision (benefit)  17.5  (32.5)  21.0  (66.8)
    Income tax provision (benefit)  16.1  4.1   17.7  (3.5)
    Net income (loss) $1.4 $(36.6) $3.3 $(63.3)
             
    Net income (loss) per common share:        
    Basic $— $(0.09) $0.01 $(0.18)
    Diluted $— $(0.09) $0.01 $(0.18)
    Weighted average shares used in calculating net income (loss) per common share:        
    Basic  419,440,458  416,680,429   418,587,390  352,337,767 
    Diluted  451,499,913  416,680,429   454,094,374  352,337,767 



    Table 3
    R1 RCM Inc.
    Consolidated Statements of Cash Flows
    (In millions)
      (Unaudited)  
      Year Ended December 31,
       2023   2022 
    Operating activities    
    Net income (loss) $3.3  $(63.3)
    Adjustments to reconcile net income (loss) to net cash provided by (used in) operations:    
    Depreciation and amortization  278.3   172.0 
    Amortization of debt issuance costs  5.7   3.6 
    Share-based compensation  64.2   59.8 
    CoyCo 2 share-based compensation  7.3   5.1 
    Loss/(gain) on disposal and right-of-use asset write-downs  10.0   21.1 
    Provision for credit losses  34.6   11.8 
    Deferred income taxes  (14.6)  (6.8)
    Non-cash lease expense  11.5   14.0 
    Other  12.3   6.5 
    Changes in operating assets and liabilities:    
    Accounts receivable and related party accounts receivable  (44.0)  (51.8)
    Contract assets  (15.2)  (24.1)
    Prepaid expenses and other assets  3.9   (40.5)
    Accounts payable  (10.9)  (16.0)
    Accrued compensation and benefits  17.4   (69.5)
    Operating lease liabilities  (18.0)  (18.9)
    Other liabilities  17.9   (1.7)
    Customer liabilities and customer liabilities - related party  (23.6)  (11.2)
    Net cash provided by (used in) operating activities  340.1   (9.9)
    Investing activities    
    Purchases of property, equipment, and software  (102.5)  (93.5)
    Payment for business acquisitions, net of cash acquired  —   (847.7)
    Other  (0.3)  (8.3)
    Net cash used in investing activities  (102.8)  (949.5)
    Financing activities    
    Issuance of senior secured debt, net of discount and issuance costs  —   1,016.6 
    Borrowings on revolver  30.0   50.0 
    Payment of debt issuance costs  —   (1.0)
    Repayment of senior secured debt  (53.9)  (25.5)
    Repayments on revolver  (130.0)  (30.0)
    Payment of equity issuance costs  —   (2.0)
    Exercise of vested stock options  1.3   4.6 
    Purchase of treasury stock  —   (39.3)
    Shares withheld for taxes  (26.5)  (30.2)
    Other  5.2   (0.2)
    Net cash (used in) provided by financing activities  (173.9)  943.0 
    Effect of exchange rate changes in cash  0.1   (3.6)
    Net increase (decrease) in cash, cash equivalents, and restricted cash  63.5   (20.0)
    Cash, cash equivalents, and restricted cash at beginning of period  110.1   130.1 
    Cash, cash equivalents, and restricted cash at end of period $173.6  $110.1 



    Table 4
    R1 RCM Inc.
    Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA (Unaudited)
    (In millions)
             
      Three Months Ended

    December 31,
     2023 vs. 2022

    Change
     Year Ended

    December 31,
     2023 vs. 2022

    Change
       2023  2022  Amount %  2023  2022  Amount %
    Net income (loss) $1.4 $(36.6) $38.0  (104)% $3.3 $(63.3) $66.6  (105)%
    Net interest expense  31.6  28.7   2.9  10 %  126.9  64.0   62.9  98 %
    Income tax provision (benefit)  16.1  4.1   12.0  (293)%  17.7  (3.5)  21.2  (606)%
    Depreciation and amortization expense  72.7  64.2   8.5  13 %  278.3  172.0   106.3  62 %
    Share-based compensation expense  15.3  15.8   (0.5) (3)%  64.2  59.7   4.5  8 %
    CoyCo 2 share-based compensation expense  1.9  2.1   (0.2) — %  7.3  5.1   2.2  — %
    Other expenses (1)  28.7  47.3   (18.6) (39)%  116.6  189.8   (73.2) (39)%
    Adjusted EBITDA (non-GAAP) $167.7 $125.6  $42.1  34 % $614.3 $423.8  $190.5  45 %



    (1) For details see Note 14, Other Expenses, to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K.

     
    Table 5
    R1 RCM Inc.
    Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services (Unaudited)
    (In millions)
             
      Three Months Ended

    December 31,
     Year Ended

    December 31,
       2023  2022   2023  2022
    Cost of services $441.6 $435.5  $1,769.7 $1,446.9
    Less:        
    Share-based compensation expense  10.9  7.4   41.6  28.1
    CoyCo 2 share-based compensation expense  0.4  (0.3)  1.8  0.7
    Depreciation and amortization expense  72.5  63.8   277.1  170.8
    Non-GAAP cost of services $357.8 $364.6  $1,449.2 $1,247.3



    Table 6
    R1 RCM Inc.
    Reconciliation of GAAP Selling, General and Administrative to Non-GAAP Selling, General and Administrative (Unaudited)
    (In millions)
             
      Three Months Ended

    December 31,
     Year Ended

    December 31,
      2023 2022 2023 2022
    Selling, general and administrative $55.7 $54.3 $220.0 $172.5
    Less:        
    Share-based compensation expense  4.4  8.4  22.6  31.6
    CoyCo 2 share-based compensation expense  1.5  2.4  5.5  4.4
    Depreciation and amortization expense  0.2  0.4  1.2  1.2
    Non-GAAP selling, general and administrative $49.6 $43.1 $190.7 $135.3



    Table 7
    R1 RCM Inc.
    Consolidated Non-GAAP Financial Information (Unaudited)
    (In millions)
             
      Three Months Ended

    December 31,
     Year Ended

    December 31,
       2023  2022  2023  2022
    Net operating fees $369.1 $344.9 $1,455.9 $1,309.7
    Incentive fees  23.9  25.9  108.4  106.8
    Modular and other  182.1  162.5  689.9  389.9
    Net services revenue  575.1  533.3  2,254.2  1,806.4
             
    Operating expenses:        
    Cost of services (non-GAAP)  357.8  364.6  1,449.2  1,247.3
    Selling, general and administrative (non-GAAP)  49.6  43.1  190.7  135.3
    Sub-total (non-GAAP)  407.4  407.7  1,639.9  1,382.6
             
    Adjusted EBITDA $167.7 $125.6 $614.3 $423.8



    Table 8
    R1 RCM Inc.
    Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance (Unaudited)
    (In millions)
      
     2024E
    GAAP Operating Income Guidance$105-135
    Plus: 
    Depreciation and amortization expense$330-350
    Share-based compensation expense$80-90
    Strategic initiatives, severance and other costs$105-125
    Adjusted EBITDA Guidance$650-670



    Table 9
    R1 RCM Inc.
    Reconciliation of Total Debt to Net Debt (Unaudited)
    (In millions)
        
     December 31, December 31,
     2023 2022
    Senior Revolver$— $100.0
    Term A Loans 1,162.5  1,211.4
    Term B Loan 493.8  498.7
    Total debt 1,656.3  1,810.1
        
    Less:   
    Cash and cash equivalents 173.6  110.1
    Net Debt$1,482.7 $1,700.0


    Primary Logo

    Get the next $RCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RCM

    DatePrice TargetRatingAnalyst
    8/8/2024Overweight → Equal-Weight
    Morgan Stanley
    8/1/2024Overweight → Equal-Weight
    Stephens
    8/1/2024Outperform → Market Perform
    Leerink Partners
    8/1/2024Buy → Hold
    Jefferies
    4/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    3/20/2024$16.00Neutral → Buy
    Citigroup
    2/26/2024$14.00Outperform
    Leerink Partners
    1/3/2024$14.00Overweight
    Barclays
    More analyst ratings

    $RCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Shift4 Payments Set to Join the S&P MidCap 400

      NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Shift4 Payments Inc. (NYSE:FOUR) will replace R1 RCM Inc. (NASD:RCM) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 20. TowerBrook Capital Partners and Clayton, Dublier & Rice will acquire R1 RCM in a transaction expected to be completed on or about November 19. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector November 20, 2024 S&P MidCap 400 Addition Shift4 Payments FOUR Financials S&P MidCap 400 Deletion R1 RCM RCM Health Care For more information about S&P Dow Jones Indices, ple

      11/15/24 6:15:00 PM ET
      $FOUR
      $RCM
      $SPGI
      Business Services
      Consumer Discretionary
      Other Consumer Services
      Finance: Consumer Services
    • James Hardie Industries Announces Global Leadership Appointment

      Rachel Wilson appointed as Chief Financial Officer (CFO) James Hardie Industries plc ((ASX: JHX, NYSE:JHX), the world's #1 producer and marketer of high-performance fiber cement and fiber gypsum building solutions, today announced the appointment of Ms. Rachel Wilson as Chief Financial Officer, effective immediately. As a member of the global executive team, Ms. Wilson will report directly to Chief Executive Officer Aaron Erter. Ms. Wilson was appointed after Jason Miele stepped down as Chief Financial Officer. Mr. Miele will remain with the Company for three months as an advisor to the Chief Executive Officer for special projects and will thereafter depart the organization. "I would li

      8/16/23 9:50:00 PM ET
      $JHX
      $RCM
      Building Materials
      Industrials
      Other Consumer Services
      Consumer Discretionary
    • R1 Announces Appointment of Agnes Bundy Scanlan to Board of Directors

      MURRAY, Utah, Aug. 12, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of Agnes Bundy Scanlan, president of The Cambridge Group LLC, to the company's board of directors, effective August 11, 2021. Ms. Bundy Scanlan has more than 30 years of experience across regulatory risk management, compliance, and consumer financial protection. She has served as president of The Cambridge Group LLC, a regulatory risk management advisory firm, since May 2020. Prior to this role, Ms. Bundy Scanlan served as senior advisor at Trelian

      8/12/21 8:00:00 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary

    $RCM
    SEC Filings

    See more
    • SEC Form POSASR filed by R1 RCM Inc.

      POSASR - R1 RCM Inc. /DE (0001910851) (Filer)

      11/19/24 4:26:18 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • SEC Form S-8 POS filed by R1 RCM Inc.

      S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)

      11/19/24 4:18:28 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • SEC Form S-8 POS filed by R1 RCM Inc.

      S-8 POS - R1 RCM Inc. /DE (0001910851) (Filer)

      11/19/24 4:17:27 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary

    $RCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RCM
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13D/A filed by R1 RCM Inc.

      SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)

      11/22/24 4:06:56 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by R1 RCM Inc.

      SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)

      11/19/24 4:36:38 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13D/A filed by R1 RCM Inc.

      SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)

      8/5/24 7:31:56 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • Director New Mountain Capital, L.L.C. disposed of $1,944,593,908 worth of shares (135,985,588 units at $14.30) (SEC Form 4)

      4 - R1 RCM Inc. /DE (0001910851) (Issuer)

      11/22/24 4:05:14 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • Director Dill David M returned $708,165 worth of shares to the company (49,522 units at $14.30), closing all direct ownership in the company (SEC Form 4)

      4 - R1 RCM Inc. /DE (0001910851) (Issuer)

      11/19/24 5:37:21 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • Director Henneman John B Iii returned $1,255,040 worth of shares to the company (87,765 units at $14.30), closing all direct ownership in the company (SEC Form 4)

      4 - R1 RCM Inc. /DE (0001910851) (Issuer)

      11/19/24 5:35:59 PM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • R1 RCM Reports Third Quarter 2024 Results

      MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year. The quarter reflects impacts to both revenue and costs as

      11/5/24 7:00:00 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • R1 RCM Reports Second Quarter 2024 Results

      MURRAY, Utah, Aug. 07, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2024. Second Quarter 2024 Results: Revenue of $627.9 million, up $67.2 million or 12.0% compared to the same period last year.GAAP net loss of $7.6 million, compared to net loss of $1.0 million in the same period last year.Adjusted EBITDA of $156.1 million, compared to adjusted EBITDA of $142.9 million in the same period last year. The quarte

      8/7/24 7:00:00 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion

      MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investment vehicle controlled by TowerBrook is currently the beneficial owner of approximately 36% of the Company's outstanding shares of common stock, including the warrant held by TowerBrook.

      8/1/24 7:30:34 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary

    $RCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TowerBrook and CD&R Complete Acquisition of R1 RCM

      MURRAY, Utah, Nov. 19, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. ("R1"), a leader in automating revenue management for healthcare providers, today announced that investment funds affiliated with TowerBrook Capital Partners ("TowerBrook") and Clayton, Dubilier & Rice ("CD&R") have completed their previously announced acquisition of R1. On August 1, 2024, TowerBrook, CD&R and R1 announced that they had entered into a definitive merger agreement under which all outstanding shares of R1 common stock that TowerBrook did not own would be acquired for $14.30 per share in cash, valuing R1 at approximately $8.9 billion. With the completion of the transaction, R1's common stock has ceased trading and w

      11/19/24 9:06:28 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • Shift4 Payments Set to Join the S&P MidCap 400

      NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Shift4 Payments Inc. (NYSE:FOUR) will replace R1 RCM Inc. (NASD:RCM) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 20. TowerBrook Capital Partners and Clayton, Dublier & Rice will acquire R1 RCM in a transaction expected to be completed on or about November 19. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector November 20, 2024 S&P MidCap 400 Addition Shift4 Payments FOUR Financials S&P MidCap 400 Deletion R1 RCM RCM Health Care For more information about S&P Dow Jones Indices, ple

      11/15/24 6:15:00 PM ET
      $FOUR
      $RCM
      $SPGI
      Business Services
      Consumer Discretionary
      Other Consumer Services
      Finance: Consumer Services
    • R1 RCM Reports Third Quarter 2024 Results

      MURRAY, Utah, Nov. 05, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2024. Third Quarter 2024 Results: Revenue of $656.8 million, up $84.0 million or 14.7% compared to the same period last year.GAAP net loss of $19.9 million, compared to net income of $1.3 million in the same period last year.Adjusted EBITDA of $148.2 million, compared to adjusted EBITDA of $161.5 million in the same period last year. The quarter reflects impacts to both revenue and costs as

      11/5/24 7:00:00 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary

    $RCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • R1 RCM downgraded by Morgan Stanley

      Morgan Stanley downgraded R1 RCM from Overweight to Equal-Weight

      8/8/24 8:58:18 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • R1 RCM downgraded by Stephens

      Stephens downgraded R1 RCM from Overweight to Equal-Weight

      8/1/24 9:39:53 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary
    • R1 RCM downgraded by Leerink Partners

      Leerink Partners downgraded R1 RCM from Outperform to Market Perform

      8/1/24 9:39:53 AM ET
      $RCM
      Other Consumer Services
      Consumer Discretionary